Tovorafenib (Ojemda) — Findings at a Glance

Public-domain competitive intelligence for the plixorafenib comparison · prepared for Shubin / Fore

Tovorafenib data public + cited · plixorafenib = Shubin-slide template only · resolve flags before external use

Bottom line: Tovorafenib is the first-in-class option for the BRAF-fusion majority of pediatric LGG (type II dimer inhibitor). Its headline response rate is criterion-dependent — 67% RANO-HGG (primary) vs 51% RAPNO-LGG (label) on the same patients — so any head-to-head must fix the criterion first. Safety is manageable (no boxed warning); the frontline FIREFLY-2 readout (~mid-2027) is the inflection. The plixorafenib side of the comparison is a Fore-internal template to complete.

The findings most useful

EFFICACY · watch

Fix the response criterion before any head-to-head

ORR is criterion-dependent, so fix the criterion before comparing: 67% RANO-HGG (prespecified primary) vs 51% RAPNO-LGG (FDA label) on the same FIREFLY-1 Arm 1 patients — the ~16-point gap is a criteria artifact, not a difference in tumor control. Criterion labels are applied inconsistently across Day One's own materials (SNO 2025 calls 53% 'RAPNO-LGG' while the label calls 51% 'RAPNO-LGG').

MECHANISM · moat

First-in-class for the BRAF-fusion majority

First-in-class for the fusion majority: as a type II RAF-dimer inhibitor, tovorafenib owns the BRAF-fusion (KIAA1549::BRAF) majority of pediatric LGG that type I inhibitors (dabrafenib) cannot serve without paradoxical MAPK activation — its core mechanistic and commercial moat.

SAFETY

Manageable pediatric profile, no boxed warning

Manageable pediatric safety with no boxed warning: Grade >=3 TRAEs 42%, permanent discontinuation only 7%, no confirmed DILI, no meaningful QT signal; the differentiating liabilities are major/tumoral hemorrhage (one fatal, 'FDA: 1 patient (1%)') and reversible growth-velocity suppression without growth-plate closure.

RWE · risk

Real-world evidence is still trial-derived

RWE is still essentially trial-derived: all durability, treatment-free-interval, rebound (31%), retreatment (-38.3%), and growth-recovery data come from the FIREFLY-1 extension, not independent cohorts; the only true independent RWE is a single 8-patient off-label adult Mayo Clinic series (SNO 2025). This is the central interpretive risk for the dossier.

REGULATORY

US accelerated + EU conditional; indication is BRAF-restricted

Regulatory scope is US (accelerated, 23 Apr 2024) + EU (conditional MA, 20 Apr 2026, EMA authoritative); the binding EMA indication is restricted to BRAF fusion/rearrangement or V600, R/R — never reproduce Ipsen's 'regardless of BRAF alteration' promotional headline as the indication. Japan = orphan designation only; other regions unverified.

PIPELINE

FIREFLY-2 (frontline) is the inflection — topline ~mid-2027

FIREFLY-2 is the key inflection: frontline Phase 3 vs investigator's-choice chemo, fully enrolled 8 May 2026 (~140 sites, ~400 patients), topline expected mid-2027 — required to convert accelerated approval to traditional approval and to contest chemo / dabrafenib+trametinib in first line. Conversion has NOT yet occurred.

COMMERCIAL

Fast ramp; acquired by Servier (~$2.5B)

Fast commercial ramp under new ownership: FY2025 U.S. net revenue $155.4M (+172% YoY), 4,635 prescriptions (+181%), 2026 guidance $225-250M; Servier acquired Day One for ~$2.5B ($21.50/share, closed 23 Apr 2026); Ipsen holds ex-U.S. rights and is the EU MA holder.

GUARDRAIL

Plixorafenib column is a template only (HITL)

The plixorafenib column is a template only: every plixorafenib cell (FORTE Sub A/Sub B, PLX120-03) carries ONLY Shubin-slide figures, is Fore-internal/embargoed and UNVERIFIED here, and is left for the Fore team to complete from cleared internal data — no plixorafenib efficacy/safety was researched, inferred, or fabricated.

Go deeper

Full Intelligence Dossier → Head-to-head comparison

The full dossier carries the mechanism/PK, FIREFLY-1 efficacy by BRAF class, safety detail, RWE, region-by-region regulatory status, commercial/IP, 36 references, and a 41-item verification-flag appendix. Two team actions: complete the plixorafenib comparison column from cleared FORTE/PLX120-03 data, and refresh tovorafenib figures to the SNO 2025 three-year cut.

Built from a 15-agent public-domain research pipeline (0 errors). Competitive intelligence — not medical advice, not promotion. Confirm every figure against its cited primary source before external or regulatory use.